BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - FRA:BRM - US1101221083 - Common Stock
40.16 EUR
-0.83 (-2.01%)
Taking everything into account, BRM scores 6 out of 10 in our fundamental rating. BRM was compared to 49 industry peers in the Pharmaceuticals industry. BRM has an average financial health and profitability rating. BRM scores decently on growth, while it is valued quite cheap. This could make an interesting combination. BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
In the past year BRM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BRM reported negative net income in multiple years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BRM's Return On Assets of 5.33% is in line compared to the rest of the industry. BRM outperforms 52.00% of its industry peers.
Looking at the Return On Equity, with a value of 28.96%, BRM belongs to the top of the industry, outperforming 86.00% of the companies in the same industry.
BRM's Return On Invested Capital of 15.09% is amongst the best of the industry. BRM outperforms 82.00% of its industry peers.
BRM had an Average Return On Invested Capital over the past 3 years of 10.96%. This is below the industry average of 15.25%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(15.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 15.09% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
The Profit Margin of BRM (10.58%) is comparable to the rest of the industry.
With an excellent Operating Margin value of 30.27%, BRM belongs to the best of the industry, outperforming 84.00% of the companies in the same industry.
BRM's Operating Margin has declined in the last couple of years.
The Gross Margin of BRM (73.92%) is better than 70.00% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BRM is creating some value.
BRM has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BRM has less shares outstanding
Compared to 1 year ago, BRM has a worse debt to assets ratio.
2.2 Solvency
BRM has an Altman-Z score of 2.06. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of BRM (2.06) is worse than 60.00% of its industry peers.
The Debt to FCF ratio of BRM is 3.37, which is a good value as it means it would take BRM, 3.37 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.37, BRM is doing good in the industry, outperforming 62.00% of the companies in the same industry.
BRM has a Debt/Equity ratio of 2.56. This is a high value indicating a heavy dependency on external financing.
BRM has a Debt to Equity ratio of 2.56. This is amonst the worse of the industry: BRM underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.06 |
ROIC/WACC1.7
WACC8.88%
2.3 Liquidity
BRM has a Current Ratio of 1.21. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a worse Current ratio (1.21) than 62.00% of its industry peers.
BRM has a Quick Ratio of 1.11. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM's Quick ratio of 1.11 is fine compared to the rest of the industry. BRM outperforms 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 391.24%, which is quite impressive.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
Looking at the last year, BRM shows a small growth in Revenue. The Revenue has grown by 2.57% in the last year.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
3.2 Future
The Earnings Per Share is expected to grow by 36.14% on average over the next years. This is a very strong growth
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.00% yearly.
EPS Next Y477.2%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
EPS Next 5Y36.14%
Revenue Next Year-1.22%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.48%
Revenue Next 5Y-5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BRM is valuated cheaply with a Price/Earnings ratio of 7.00.
92.00% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (27.30), we can say BRM is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.74, the valuation of BRM can be described as very cheap.
BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 88.00% of the companies in the same industry.
BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7 | ||
| Fwd PE | 7.74 |
4.2 Price Multiples
BRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRM is cheaper than 92.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 94.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.57 | ||
| EV/EBITDA | 6.22 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM has a very decent profitability rating, which may justify a higher PE ratio.
BRM's earnings are expected to grow with 73.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y130.91%
EPS Next 3Y73.4%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.22%, which is a nice return.
Compared to an average industry Dividend Yield of 3.04, BRM pays a better dividend. On top of this BRM pays more dividend than 92.00% of the companies listed in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.22% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
98.12% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.12%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
FRA:BRM (9/12/2025, 7:00:00 PM)
40.16
-0.83 (-2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners84.14%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap81.74B
Analysts67.27
Price Target44.45 (10.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.22% |
Yearly Dividend2.06
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)-2.1%
PT rev (3m)-9.17%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)-1.1%
EPS NY rev (3m)-5.33%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.92%
Revenue NY rev (1m)2.16%
Revenue NY rev (3m)2.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7 | ||
| Fwd PE | 7.74 | ||
| P/S | 2.01 | ||
| P/FCF | 6.57 | ||
| P/OCF | 6.02 | ||
| P/B | 5.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.22 |
EPS(TTM)5.74
EY14.29%
EPS(NY)5.19
Fwd EY12.92%
FCF(TTM)6.11
FCFY15.22%
OCF(TTM)6.67
OCFY16.6%
SpS20
BVpS7.31
TBVpS-10.78
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 15.09% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 95.64% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-16.88%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.06 |
F-Score7
WACC8.88%
ROIC/WACC1.7
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
EPS Next Y477.2%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
EPS Next 5Y36.14%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
Revenue Next Year-1.22%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.48%
Revenue Next 5Y-5%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year268.01%
EBIT Next 3Y49.33%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%